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Abstract
High rates of unprotected sexual behavior in adolescent;;
result ln rniUio:as of sex.t;.ally trar:~,mitted disea..'\es (S't'T>s) in
the world. This paper reviews factors inducing high STD
rates, specific STD\ and their ma:nagement based o n 2010.
US Centers for Disease and Prevention (CDC) STD
guidelines. Clinicians should screen all their s~xually active
adolescent patient$ [i).t STDs a::.td prov ide prc,..'entivc
educatiqn a~ well as tn:atment measures.
Kejo·word!i: Adolescence, sexu~lly transmitted dise-ases,
STD

Intn~du.ction
There are many sexually transmitted diseases (STDs),
wbkh can i.nlect adolescents (see- Table 1) (l-5).
Sexually active adolescents arc at risk for STDs due
to th6r high rates of sexual a(;tivity, multiple sex
partners, immatw.'e cervix (cervical ectropion which is
a good med·ia for gmwth of s.o me STD \igents), other
high risk behaviors that crrcourage sexual behavior
(i.e., substance abuse; hocly pierci ng; tattoqs), mistrust
of adults in general, problems traversing the tnGdkal

system, and an often pervasive belief ("magical
thinking'') that they are not sqsceptib1e for acquiring
STDs. The growth of social networks in the past 20
years has led to another avenue fur allo\oving youth to
meet. and acq uire STDs. Adolescents receive limited
$exua1 ~ducation in the United States, have .accidental
or irregular sexual relationships, change sexual
part.'1t.."Ts ("serial mon ogarny"), and tail to use

···········--------Con:~spond~euce:
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condoms on a regular basis.
The result is that 19 million STDs are acquired in
the United Siates each year, mainly in the 14 to 29
year old age group. One in six sexually active
adolescents (15 to 19 years of age) acquires an STD
each ye<Jr, and one in three persons acquire an STD by
age 24 years. Those at the highest risk. for an STD
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include runaway youth, those tTIV(.i!ved fn survival sex
(prostitmion), those in jails or detention cen ters, those
involved in u1ale hom•Jscxuat activity, and youih w:ith
a histo ry of .STDs. The most .c ommon ST.Ds amun.g
youth arc infections due to hu:man papillomavirus
(HPV (6-9), herpes simplex. virus (HSV (10,1 1)),
chlamydia trachomatis (12,13), neisseria gononhe<le
(14) and trichomonas vaginalis 1.5-19). The highest
rates of chlamydia! ?.mi gonococcal init~dions are in
i 5 to 19- year old fem<.~les, while HPV a(;quisition is

Hr~tim

A Omar, et at.

often during adolescence. Oral ~exual hdJ.avior is
noted in one-third to one·half pfyouth and can lead to
the acquisition of various STDs including HPV,
herpes simplex virus (HSV)., syphili~, gonorrhea, and
others. Clinicians should note that Neisseria~
g(morrhoeae is part of the differential diagnosis of
pharyngitis in adolescents (see Table 2) and th,is,
questions about oral :;ex-nal behavior are important
c~ven when snre throat is the on1y presentation.

T:tblc L STU ,-\gmHs (Diseases w: Jnfections; STDs; STili)

Trichomonas vagina/is
Chlamydia irachommls
Neisseria g-:morrhoeae

[

: l!aemophilt<.s decreyi (Chancre:d)
Pediculost.;· pubis
1:
Sarcoptes scabiei (scabies)
Gardne:ella va/?tnalis (Bacterial. Vaginosis)
' (Sexually assocmted)
Klehsi!ilia granulamatis (Lymphogranuloma venereum)

i

Ii
i
I.
,___

. ~-!erpes ~irnple.-::_ viru..~ .CHPV).

. ,
tli:m)an tmmunodeficwncy Vlf'I.IS (HI\·)

Treponen;a pafli(iwn (syphWs)
Molloscum {:ontagiosurn
i Donovania granulomatis (Granuioma .ingpinale)
i

--,

.. ...

.......

Behc~et's dhease
Reit.::r's .syndrome
........----"--·Others
""'-----.........

___

__

.......

____

---~·

i

I
........

i

.

!

1

..............

........--.- ..........-

~

(HPV) .............- -.........- - -..·r-il~patitis A, H:..E·..·-._

.

H;;;.~~ Papil;:;;;;;;;~irus

.

r·

T.ahle 2. Differential Diagnos~s of Exudative, Diffuse, m· M.emb!·iuwlfs Pha.ryngith

~~~~~e

::::::::==:-·---~~:::::n>-.7". criptt_2~:____ :=::====·-·--·=:::::::::==:____. :=.

i Group A B- hemolytic
:
j

Strepm cvca£~

.l

I
.)

[

~.~~Te,.Ji~>u~-~;;m~nucleosis

: ,i:pst~:m-Barr v:rus)
1
1

I
l.

j Exudative, cii.ffuse, or mcmbran.ous typ~.· 0. ther feat11res:
! stra>vbcrry tongue, tc.nd<!r anterwr cerv1c.al
lymphadenopathy, fever, leukocytosis, qysphagia., liild
' headache. Minimal coryza and cough. P{lSitive throa~
culture. Scarl~t fever can oc:c:;lr. Can occur w1th
1 inkctk>.us mmtonuckosis.
i
:
_..........
,: Exudative·:·ilim...s~~..;;;·;ncmbran_ou,s e;y·tl~~roa. Pe~iodic
fever, lymrhadenopath:Y (espe:cJalJy antenor cerv;cal),
: splenm~~galy~ a~sol~tc iym.phocyt<,sis, po!iti;'e
hcteroptll agg!utmatlot; tc~{ (or other serq;og1c

Gon;;~;~~ccalph·~·~·y·;g;·(·~s·

J

i tr~:~!~~.(:.r.l_t
~
~· 1.2 :n..=·.l.!.·ion U benza1J.;ine
1
_pe111c;ll;n IM or oral
[
pen(c;Hin, 250 mg, q!d X 10 l
j day!;; .crythrorr:yc.in, 2.50
i
i mg, qid x 10 day:.
I
r~efador
'"! 5(' m:~ q·t' U·~
!:
' """
~)•· ~

-.- .....:::::::::::...

I

1

h ......--................._

AdenGvinJ.s pharyngitis

I (coxsackievirus A,n)
.---......

.

·· ~ ·~ ·

i
i

·i :.·:·.,'

j
J

---l
·
,,.

lf
~9:2~~:.a, ana' c9.~P~1.
...............- · - - -...:......------ ll
................___..................~!
Raised; whlte or yd!ow lesions >vith surrounding
l Supportive.
• ·th • ·· "' !' · ~r t ••· ~ h" ·.
:I
1 c.ry .crr.a ,,1 ne.}'·)S C·d O. ·p ... rynx.
1:

i

i

! ne;pmgi~~............ ~---·t·'i~~puloves·i~~·iarf~si~;·~~··ic~ding ro \Jlc~;:~t·i·o;Js occu;·~;~lsui)i;ort'i~c.
1. (coxsa(;k\evirus A)
! th~ phary~x: Pr~sents ~s a febrHe ilin~ss -often in;he .
1

!

l

!;
l

·~·

;

!"s·~~~o;~i~:~· ··~r~:......._ _ ,

~~~~i~~~:~~~:~~~;~~I~: ;~~ii1:R~~;~~~~~)~ma oTth~~--............!I Ceft;i;x;~~:··:iS'o mg JM ·::·....

I.

i Acute lymphonodular
!1 ,.,:
"' v n.,.1,,s
,,·.:'
... ,l~r~

(>

oropharynx associ<~tcd with antcrim cervicai
tr,~atment fm Chlamydia
lymphadenc}palhy and hlstory of m.·al sex with an
trachomatL;;: SC(O Tabie ;5.
inf~ct~;d ~exuai partner. Often asymptomatic. Pharynx
1nay he the on.ly site nfin:f edlo n in 1%-4% of teenager~ b :
\Vith r~onorrhea.
.......
C't)~i.m:ol) ca~~~;· of 1\0~·~i:~~r;;{;'~~x:cal exudati~~--·-....·-· Supp~·;~(i~.:e~
pharj'ngitis and nasopha;:yngitis and fo!Hcular
]
i
phrJyn.gitis; difft:sc erythema alst.\ noted, with fever,

(Ne.i5seria gonorrh.oeae_)

I!_ ,,.,
_ ...,....-...,--··-··.....-......

•

F v iQr{ ..... ·,.,. 0 t1'\n

................l~!~~r- t~cn.o:.~~_s an

entcro\~!.Hf!:.:l::~? ime1J0~~~-·-·__..L...

,

..........----<

i

.............___.....,

...................._ _ __ _ _ _ _ _ _lillilllil_ _ _ _ _ _ _ _ _ _ _ _ _ _ _~
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L:i~~~:0;~:::::::~:~:~:~=:~:~::::::·------,·-····n:~~~~IP.:~C~~:~:~:::=::::~:~:~:~::::~:~~:::::~::::~::::~:~::::ri:~~~~in~:~1::::::::::::::::::::::::::::::::~:::::~:::::::::::::::::::;
i Hand, foot, and mc;ctth
Vcsic-lllar and dcer~tive lesions ;n the
S·upporlwe.
!
i disease (coxsackievirus A
mouth. and pharynx with ve~icdar eruptions
!
i
ever hands and feet.
_______ j
16)

i Postang:na1. sepsis
!

(f"usiJb:.u~terir:~n'l nect'(Jphartitn

!!' and Bucteroid:::s sper;ies)
-

!

i Co-;);:~b-:_;~t;.;:;~:;;_-·

i:a.'~~~~:::~

·

Evidence Gf pharyngeal infection fi;iJo,•;ed
by high fever, chH-is~ anterior cet,. icitis_,
multiole abscesses, jaundke, etc.

E8.\iscci"i)~:·artaerci;fC hacterk Treat-

:

rnent invol-Ve~ antibiotics··· pending on
cuiturc results- penicillin,

,t
dindarnvcin. mctronidaznlc. elt:.
i
Variabt'Z;pb~~-;~;.-g}ti~·~;~:;~i-;;t~d with ;-.......,..r~:~·yt·h;~;;~;;;~;;~~-2-so··;.~~~:··,]i~f~--'['{}-~[-~·);;:----~
L·

! Penicillin not reliable.

_______;~~:~;~~~:;iE::,:~::oct·:· J
scarlatiruf!mll enmtion of arms and legs

I

_ .____j

H eprlnted wlth nermission frc,m: Ch:ydarms Dt-:: "Disorders of the ears, eyes, nose. and throat." In: Adolescent Medicine,
Third Edition, Eds:
AD Hofmann, DE Greydanus Stamford, CT: Appkwn & Lange, ch. 8: page lOG, 1997.

Primary prcvemkm of STD~> it1vnlves proper
(:ounsding of youth regarding STDs (including H IV),
use of latex condoms for all sexual encounters, and

immunization with HPV, Hepatitis A, as well as
Hepatitis B vaccines {including for males having sex
\Vith men and illicit drug users).
Use of a condom is a marker for improved risk
behavior in adolescents and is beneficial in h_;wcring

STD

rates,

especially for N

gonorrhoeae,

C

irachomatis and HlV, Spermicides with nonoxynoi-9
are riOt recommctH.l.ed at this time because of their
failure to prevent various. S'IDs and potential injury to
the surface of epithelia] cells linked with its usc that

may enhance the acquisition of HJV.
Secondary prevention of STDs involves regular
STD screening of aH sexually active yout:.'1, evaluation
for STDs, proper treatment of i.demified STDs
(including asymptomatic infectint1 }, and partner
notification in the presence of STDs.
Screening sexur::lly active teenagers and adt1 Its
indudes annual testing for chbJ.""hydia. tmchomatis (up
to age 25 years), annual testing for neisscria
gonorrhoeae if at risk, and annual HIV screening if
sexuc:.lly active as weB as using injection drugs. Self..
collection vaginal swabs and mine samples for C
tradmmatis and N gonorrhoeae are becoming
increasingly acceptable to adolescent females.
One should consult with the CDC 2010 STD

guide!ines for STD management including STDs in

,·.· ~·

Chlamydia trachomatis
Two species of Chlamydia are recognized: Chlamydia
psittaci
(causing psittacosis) and chlamydia
trachoma1i.s. The latter consists of different subspecies
which can cause ccrvldtls, urethritis, trachoma and/or
lytnpbogranuioma venereum.
Chlamydia trachomatis is an obligate intracellular
mictobe which causes the most commonly reported
bacterial STD in the United States and as noted with

STDs, is disproportionately increased in minority
adolescent females. H causes cell da...rnage with a
significant inflammatory host ceil irntnune response.
Tw·n to three million infections arc estimated to occur
each year in the US and the prevalence in 18 to 26

year olds is nearly 5~·o in females and nearly 4% in
males.
Chlamydia trachoma.tis is a bacteria that can
cause a variety of inJections (Table 3) t..l-Jat include
cervicitis, urethritis (vvith dysuria, m'ethra! discharge
[often thin]), epididymitis, proctitis, pharyngitis,
proctitis, perihepatitis (Fitz-Hugh-Curtis syndrome),
and endocetvldtis (pelvic infla:nmatory disease--PTD}

::

..

;

-:--:

·:·::

(l2,13),
AU sexually act~vc females under the age of 25
years should be screened annmdly for the presence of
this bacteria that can be silent (asymptornatic) in hJ.lf
or more of those i11fec!ed.
A variety of diagnostic tests are available. as

special circumstances, such as STDs in pregnancy,

noted in table 4, Nucleic add mnplifkution testing

males having sex with men (MS1vr), &TDs in children,
women having sex with women, those in correctional

(NAAT) and DNA probes can be done on vaginal or
cervical material as well as urine, NAAT sensitivity' is
excellent, in the rage of 87% to 97%,

i.nstitutions, and others.

·.·.....
:-:·:·:·>
.

; :~ -' <:~

il
.. .?

Hminin~~~~~~i~I~IHimiHt~I~I~I~~HI~I~t~t~t~t~I~t~t~t~t~t~~~~~i~~~i~~~i~~~iHi~~~t~t~t~t~t~t~t~i~t~t~~~t~~ni~tn~~~~im~i~t~i~j~j~
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Urethi'itis aiui epididy.mitis

Table 3. Chl;nnydaa '!'.nu:humati~ Infections

Salpingitis
Peritonitis
5. Perihepatitis (Fitz-Hugh--Curtis syndrome)
6. Urethral syndrome
(dysuria/urethral sy;1dmme)
7. Epididymitis
S. Conjunctivitis
9. Pharyngitis
l 0. Otitis media
i 1~ Pnettmonia
12. Endocarditis
13. PrGstaliti.&
14. Proctitis (LGV stain)
15. ? A!t"hritis
\
! t6. Reiter's syndmme
!
_________ :.,__
l.....________
17. Others

Urethritis due to chlamydia trachommis usually
presents \vlth dysuria and a thin or non-pun..:lent
urethral dis;;;harge; mucopurulent or pLmdent
discharge may also be seen. H may be present with
other STD agents includirlg N gorwrrhoeae,
ureaplasma urealyticum, or trichmnatis vaginatis.
Urethritis due to C trachomatis and urcaplasma
urealyticum have the same cUnical appearance and
both usually respond to doxycycline or erythromycin.

3.

4.

_______

1'.1ale methritis may also be due to mycoplasma
genitalium or herpes simplex virus. A first morning

!
!
!

. . . . . . . . ~ _j

Tabk 4. Dia.gn{lstk Tests fo:r Chlamdia tr::u:homaH.s

r··--c-en c uh~r·e·(:'&0.id--sii~;,ci;(;;;)
\ Polymerase cham reaction test (nucle[c acid
1 amplification testi11g or NAAT)
! Lig~se chait1 reaction test (NAAT)

i

Enzyme-li...'1ked immunoassay (ElA, ELISA)
\
Dir:.::et flumes cent anLibod.y (DFA)
.
i
\ DNA probes (Gcn.. Probc; (Erect hvb~;d;nition i

!

lJ~irt:<:~:~1i0~1-~~.:--~~-~~!.~~~~-~Ar.~~~p-~) , .-"-~_ _ _ _ _j

Cervicitis
This can present m various ways, though there
typica1ly 1s pun1knt or nmcopurulent cervical
discharge, vaginal ery1hema, and hypcrirophic
cervical erosion. Mixo<~d. infections with other STDs
common., especially Neisseria gonorrhoeae.
Treatment of ~::crvlcitis due to Chlamydia traclwmatis
is outlim~d in Table 5.
\Vhen diagnosis cannot be conftnned, treatment
for Neisseria gonorrboeae should be included due to
the high incidence of coinfections. Azithromycin is
effec1ive for chlamydiat infections in pregnancy.

are

void urine evaluation may reveal the presence of T.
vaginaJis in those -\Vith nongonococcal urethritis
(NCU). Dysmia associated with pyuria can be due to
chlamydia
trachornatis
(urethral
syndrome).
Pharyngitis is uncommon and usually due to N
gonorrhoeae or herpes simplex virus. Caucasian mates
with HLA-327 v.·ho develop chlamydia..! urogenital
infection .may
subsequently develop Reitct's
syndrome. Pelvic id'larnmatory disease, ectopic
pregmmcy
and infertility
may occur.
The
recomm.:nded treatment sched1~1e for uncorrtplicatd
~~hlamydia urethritis is azithromycin (1 gram oraHy in
a single dose) or doxycycline (100 mg tvvice a day
orally for 7 days) (s0e Table 5). Azithromycin is
preferred for those w·ho may be non-adherent due to
i~s single dosing regimen, while erythromycin may
lead to non-adherence due to gastrointestinal
intl>lcrance.
Alternative
treatments
include
erythromycin base (500 rng orally four times a day for
7 days), etythromydn ethylsuccinatc (&00 mg oml!y,
four Lirnes a day for 7 days). of1oxadn (300 tng orally
tv>'ic:e a day f(w 7 days) or 1evot1oxacir, (500 mg orally
fc:r 7 days). Doxycycline, ofioxacin, and k:vot1oxacin
arc contTaindi(:ated in pregnancy,
Recotnmended regimens for the pregnant patient
include azithrumycin (l gram orally) or amoxidllin--··-500 mg orally three times a day 7 days. Altema.tivt~s
for the pregnant patient include crjthromydn base
(not estolate) --son mg four times a day orany for 7
days or 250 mg PO, four times a day for 14 days:
c.J;:;o, erythromycin ethyisucdnate (400 mg, orally
f()ur times a day for 14 days or 800 rng tour times a
day fbr 7 days) can be used.

~Ir···:c

:·.·.···
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Table 6. Screen adolescents with N gonorrhoeae for C

...·: ·

trachomatis, trepon~ma pa.llidmn and H1V. Treatment
should also include coverage tor C trac.hamaris since
ir is present in. up to 40% of cas.es (Table 4).
Unfortumrtely, antibiotic resrsta.nce, a phenomenon
begun in the 20th century, is worsening in the 2lst
century; this includes resista.rrce to pen.lcillin,
tetracycline,
spectinomycit1,
quino1ones,
and

:::::.:

=·~

-::·.-.

;::;:·

::·;:

;; ..

floxacins , Other causes of mal~ \Ucihrhis arc noted
above
onder C tTachomatis. Treatment of
uncomplicated gonococcal int~~cti.on. \Jf the pharynX is
with ceftriazone (250 mg intrar1msc.ularly) plus
a;~ithromycin (1 gram oraHy} or Juxytycline (l 00 n:g

twice a day for 7 days).

Table 6. Antibiotit.~ Management of Gonoco~:ca! InfcctiMIS af the Cervix, Urethra,
or Recuun: (uneomplkatcd} ((:DC STD ( l:uidelines, 2012)
···············-·····························\

l. Ceitriaxom-\ 250 mg 1M , one dose, or (if not un option)
2. Ceflxime, 400 mg, cm;~lly, one
PLUS (For optiuns 1 pnd 2)

dos~·.

A:z:ithromycin (1 gram orally in one dose) OR Doxycycline (100 mg oral!y twice H. day-7 days) OR
3. Az1thromyc:in 2 gram dose
'"'Options 2 and 3 requir~ ;1 te~t of cl;re one \veek f~-:Jllow ing tnmtrnent

!l
!
!

::··

.,

'hblc 7~ H1agnostk Cdtcria fur Pin (2010 CDC STJJ Guidt!lioes)
~mal

Cri.t-er-:i_a_ _ _ _ _ _ _ _ _ ........._________ _ __ __ _ .................... -

a. Uterine tenderness, N
b. Adnexal tcndeli)e"~· or
c. Tenderness on cervical motion:.....-_ _ _

1

\

i

r··· ·2·.-Addition~~t -Di·i;ti~---·····-··········-·-·-···-·

:

.
)

·· :;

=:.:,

;,.

~~F

,:_: ;.

l

b. Or<l.ltemperature over 101 degrees F (over 38.3 degrees C)
c. Exainiilation of sdine drop from discharge: see white blood ed ls

!
::·::

-··················································-·- - -···············..··

a. Cervical (vaginal) mucopurulent discharge

l

.

·-·-..········!

d. Elevated C-reac:tlve ·proteb
e, Elevated eryti1rocyte sedimentation rate

L
............ f. Positive lal? test f£r C. !E~~~t~~~~_?-~is or N. gon~r::!~~-~~~..~-~-<:!t9.~?.........-----,-································i 3. Specific Cri~criaa .

'
L

1

a . Positive biopsy ofendomctrium showirlgendometritis
b. Evidence ofPlD on Japaroscopy
·
c. ~J.lt:a.sou._:_n_d -~t:a. nsvaghal) or MRI shows fallopian obes thut al'e thick and filled with fluid; may be fn~e J
... }}~P5~ m the pelVIs or a Ll.Ebo-ovana~.E~!_mplex.
_....................
·-·-....-.................................
t.

:.: ~;.
·····K~~i~- intermitt~;;:·;;·;;~:;;·;;;~;~···················-···-·---·· ············································· ···· ··· ·· ·······

-········ · ···· ······ ·········· ··· ·· · · ~ ·~···-~~-1
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Appcndi~itis

Endorne1tiosis
Ectopic pregnancy
Gastn)enteritis (as due to Yersinia enterocohtiw or Campylobacterf etus)
Hcnoch--Sdwnidn ;;yndromc
Hemolytic-uremic syndrome

.lnfhurunatory bowel disease
.Mesenteric lymphadenitis
Ovarian cyst {with or without torslon or n..tvture)
Pyelonep.hritis
Other

- - - - - - -- ---·········-···-·-··-- - -- - - --·-···········..·-- - - - - --

.· .· · · . . ·

- -.. .:

· · ·.· · . · .. · · ·. · .· · · ·.·.-- .·.·.·:/lC'&
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Sexuc(lly transmitted diseases

Pelvic inflammatory
·'
. disease (PllJ i
.

.~

P!D .is a polymicrobial infection of female genit<>l

tract that can i.nclud:;: C trachomatis and. N
gonorrhoeae, th is polymicrobial infection may
involve such agents fo und in the vagino -cervical

endogenous flora ------ such as gardnerclla vaginalis,
streptococcus, neisseTia meningitides,

bcta~hcmolytic

mycoplasma

genitali.um,

streptococcus

faccalis

ha.emophilus

bacteroides

ureaplasma

infhtenzae,

brtcteriaceac), cytornegalovi rt<s,

improvement with wntin.uation of doxycycline t(n- 1.4
days lotal. l V doxycycline iniiJsion can be very
painful aHd oral doxycycline may thus be preferred.
Ana.c:robic CDverage should be included in the

presence of a tubo--ovarian abscess.

Fitz-Hugh-Curtis syndrome

fragiHs,

urealyticum,

co1if(.)rms
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The Fitz-Hugh-Curtis Syndrome (perihepatitis) is due
to inthmmation af the liver capsule after a genital

pcptostreptoc~)ccus,

infection with neisserla gonorrhoeae or chlamydia

and other anaerobes (21,22). Screening for and

trachomatis. There m~y or may not be a symptomatic
genital infection at the time the perihepatitis presents.
Acute, severe, and knife-like right upper qaa.drant
pa.(n develops with or without right shoulder pain,
right costal margin friction rub, and abdominal

management of C trachomat:ls can help to prevent
PID. Tabl.e 7 notes CDC criteda for PID that revolve
around lo~,ovcr genital tract inflammation with pelvic
organ tenderness. ·rable 8 notes the differential
diagnosis for PID; if PID is clinically severe, consider
hospitaliz:ation and imaging to look for tubo-ovarian

abscess.
Table 9 nCltes. CDC-recommended. treatment
options that seek to provide polymicrobial antibiotic

coverage to contain the infection (inc;h1ding
facu ltative and anaerobic bact~tia) and prevent
:;equel.ae. In those with mild to moderate disease, or4l
and intravs~nous therapy are considered equaHy
effe;,;tivc. For those receiving intravenous antibiotics,
1V therapy may be stopped after 24 hours of clinical.

rebound or rigidity. Fever, nausea, emesis, hiccups,
pleurisy, and pleuri tic chest pain may also occur. T"he
erythrocyte scdim(mtation .rate (ESR) b elevated and
the. liver fu nction tests (LFT) are usually normal,
t.ho;~gh transient rise -in LFTs has been reported. A
l ap~ro~cQpy ~vi1! us ually clemonstra.te the perihepatic
intlammation and/or prese-nce of the adhesions
between the anterior abdom:inal waH and the J.iyer,
Must acute castls will have a positive cervical culture
for gonorrhea or chlamydia. The liver enzymes (if

cJc.vatcd) normafizc quickly after arJ.tibiotic treatment.

Table 9. Ant ibiotic Management of PID (2010 CDC STD G uidslines)

--·------------------------·-····-·-·-··············--------------------..........,..._,_________..........................,..........___i

ORA( ,

I

Ceftrixone 250 mg fM in a single dose OR. ccfoxitiil 2 g l.!Vl in a single dose and probenecid l. g oral.ly
concun-eutly OR other third gen.eration parenteral cephalosporin (as ceftizoximc or ecfowximc)

!

i PLUS

!
l
i

i doxy<:ydi.ne 100 mg omlly twice ~.l day for 14 days with or without metroni dazole 5DOmg orallyt\vice a day fer
14 days
!
!
i

! PARENTERAL
i
i

i
i

Re~imen

A

!

Cefntetau2 g 1V every 12 hours OR cefoxitin 2 g rv every 6 hours PLUS doxycycline lOO mg orally or JV
c-v{~ry 12 hott\'""S' Regimen ll
Clindamycin 900 mg IV every 8 hou:rs PLUS geatamici.nJoading dose N or TM (2 mgAg body \'.-eight)
f?.~-~~.~:~-~-~Y..:~.:~-~!~:~~~~~~~~-~:-~~:~~~.F- 5 mg/kg) every 8 hou:rs. Singte daily dosing (3-5 mg.tkg) can be substiL~Jted.
!.

!

L...

::~·~·~ ~:~.1·:·1' ~:~ ~::·=..: ~:: ~: . :==. ·: ·= :== .. :·=.:··= .·:

·= .. : •

:~·· .: ~ ~ ~-:

:.; :.: : ;

:·~:
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Differential d iagnosis inch1des other sour<:~s of right
upper quadrant pathology, including cholecysti tis,
pancreatitis,
peptic n!ccr disease, hepatitis,
pyelonephritis, pietldsy (with or without pneumonia),
pulmonary embolism, pleurodynia, herpes zos ter and
others. A rapid response to antibiotics is usually
noted. Som~ individuals develo p dl:ronic p<tin due to
the adhesions, requir ing lysing of them for pain relief
v ia laparoscopy. The correct diagnosis is based on a
high index of suspicion in a sexually active femal e

with right upper quadrant and gonococcal or
cnlamydial infection which improves With antibiotics
or which is confirmed via laparoscopy. Treat as per
PID management guidelines (Tabie 9) via the 2010
CDC STD treatment guidelin~s.

Disseminated gonococcal infection
Approximately 3% of women and l % of men with
gonorrhea may d evelop scptlccn:da leading to DGI,
with evidence ef dermatitis, arthritis or tenosynovitis,
perihepatitis, meningitis, endocardi~is, and others; the
most commo n fonn
DGT is the dermathis~arthritis
syndrome. The most cmmnon form o f dermatiti s is
the vesicular pustule (4 mm<?. .S em) which rs 110ted
within 2-t;. weeks of the urethral gonorrhea and is
found as 2-9 lesions on the extensor ~mrface o f the
hands, do rsal surfac~;, oJthe arJldes and toes, and other
areas. They appe<tr in crops at different times and
probabJy reprcM>nt gonococcal embolization ar <m
immttnobgi.caHy..mediated vasculitis, A pos1t1vc
Gram stain an:d./or culture of the lesions may be noted:.
T he pustuks develop i.nto pigmented lesions and dear
without scarring in 1-2 m onths. Sonretimes purpuric
macules on the palms or s<.Jles appear, as ·well a s
hemorrhagic bullae ia various areas, or a pekchlal
rash ove r the hands, feet and ankles. The oral mucosa
and
scalp
are
usually
spared ,
Secondary
"lymphadenopathy does occur.
A polyarthritis or monarthritis {tenosynovitis) has
been described in the medical literature hut the pattern
is variable. Many joints may be itwolved, including
the kr:ee, ankle, wrist, the smaH j oints of the hands or
feet stemoclavit ular joi11ts and oth~rs. The
monarticular tyrc often affects the knee. The joint
fluid is freq uent1y opaque or slightly cloudy, has a
poor mucin clot, i11creased pr(itcin and variable

or

leukocytosis
(10,000- 100,000
per
cu
mm),
Gonococc-al dermatitis (see above) and elevated
erythroGyte sedimentation rate (ESR) often occur.
Tenosyr;Qvitis (dorsa .Qf hands or feet, wrists, AchiHes
tendon and others) also occurs . The ESR rate falls
with effective therapy (Ce.ftriaxone l gram IV dai.iy
for 7 -l. 0 d ays). Jo int destruction occurs 'Nithom
treatmen t. The urethral discharge may be minimal or
absent when DGI symptoms appt~ar. Gvnococcal
arthritis dermatitis syndrome is the main. type of DGl
and is the main cause o fbacter ial ar'J.i ritis. ~n sex111J.!y
active teenagers and young adult~. Gonococcal
osteomyelitis i s a rare co mplication of gonococcal
arthritis. Rapid response to therap y is usually noted,
b ut is slow if purulent synovial effusi ons are noted .
Osteomyelitis requires a much iongcr treatment
regimen.
Treatmen t of DGI is usually with ceftdazonc (1
Gram IM ot lV) ev·~ry 24 hoors until improvement
dcvdops, often given for at least a week or more;
alternative antibiotlc:.s ar~: cefota.xime ( 1 g ram IV
every 8 hours) or cefliz.ox.ime ( l gmm l V every 8
hours). Patients should also be treated for presumed C
trachornatis. See the updated 201 2 STD guidcllnes
fro m the US Centers for Disea~e Control and
Prevention.

Herpes simplex virus
1nfcction with h~rpes simplex virus, type I, cause::; l 020 % of genital herpes while type n causes the
majority. Type 1 can lead to herpes labialis, keratitis.
eczema herpctlcum, an-d gingivosto matitis (l 0, ll ).
There is an incr ease in HSV~ 1 anogenital herpes i.n
yotmg wo mc11 and m ales having sex w ith males
(MSM). Over 50 million i.•1dividua.rs in the 11T.!!1ed
S tates (over 500 million worldwide) have genit~l
HSV infection and the high est i:m.:idence is in the
adoi~scent arid young adult age group. On!y one··
qlJarte r o f those. with HSV · 2 intection .have kno w;;
genital disease and most case~ are acquir ed from
someone without known disease because of vital
shedding in· both asymptomatic and S)"IlljJtomatic
persons . L<itency and reactivation phenom ena are
classic witJ> H SV infecti ons.
A number of clinical presentatior:s for HSV 2 are
noted, includi!lg a first clinical episode wh!.ch is.
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pri.mary (with no prior HSV history and being seronegati ve f<.w testing), a non-primary first clinical

shouid be avDided with .HSV gcnita1 infcctionsf a.mciclovir and 1talacyclovir have greater oral

episode (with a first recognized dinical episode and

bioavailabil.!ty and may offer the convenience of less
frequent dosing cmnparcd to oral acydovit. Antiviral
1reaH'nent does not eliminate latent virus. Rcseard) is
ongoing with recombinant glyco-protein vaccines
being developed .

sero-positive for HSV··l and HSV.·2), rocurren1
clinical episodes (with recogn ized, repeat dln ical
episodes and sero..positive for HSV -2) and
asymptomatic prescntat;on (with no recognized
cli.nical episode hut sero-positive for HSV-2).
Clnssic c.linicall-TSV-2 iri the female presents as a
c.crvkitis o r vulvovagini1is that has a mucopu:ruknt
discharge in asst)ciation ''tilth v~;lvat ulcerations.
There can be otbpharyng!tis, utethritis, and proctitis.
'fypk:ally there is itching or hyperesthesia followed
by a number of small-group vesicles with
erythematous bases that change or rupture into small
shallow tender ulcers. These painful iesions can
persist for 3 to l4 days before disappearing wit.hou.t

scatTing.

1'a!J1c 10. Supportive Labtrratory Dat11 fur G~nitlll
He£·pe~ Simplex InJection
.._.._...........

:---~--------- -

_,,

__________ , __ , ________________ ,_;

C¢1! culture
!
PoJymel'(:lSe Chain Rca.ct!on (PCR) :.esting (NAAT) \
HSV~spccific giycoprotciu G2 (HSV-2)
~.~
and G I (HSV- 1)

Giem.sa stain or Wright stain (TzarJ< test)
1
Pap smear
!
Electron microscopy reveals viral herpetic i
l -----------·---··-·--·--·-----------·- _i!
"--'p'-'-a_r_ti_c_e_s_.

The lesions may arise on various locations of tbQ
genit~tl.s ( vnlva, cervix, penis,

.·:.::cr.: .

.-,:.:cr:: .
.-:..:cr::.
.":..::r.: ·

··'\:\
··•t·•.:

.::..::(.: ·

·.::.: t..

••'·'•:'!.'-•
:::.:
cr:.:.
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_,,., ~. ..

: _,:,r •,

.:::::!:.'
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}!

::·:::!..

·;::ff

periu;ethra) bl!t ca.."l

spread to the vaginal, scrotum, urethra, CL"lUS, perianal
areas, rectum, thighs. or buttocks, On~e or more deeper
ulcers can be seen with primary dlscas~ in association
with fever. headache, general malaise, anorex ia, a:>ti

inguinal lymphadenopathy. Uncomrmm complications
with herpes genital infectivn include ~rythcma.
meningitis,
ascending
myelitis,
raciicu!ornye1itis (with acute urinary retention), and

mHW.P.>rme,

hepa.tit failure.
Table 10 lists supportive laboratory data; cell
culture :rod PCR (NAAT} are the recommended HSV

tests f()r symplorrlatic patients . The Giemsa or \Vrigh.t
~tain ca,n r~veal h<Illocn cells \vith intranudea.r bodies

or multinuClear giant cells with electron microscopy.
A Pap smear can reveal nmltinuclear giant cells; these
can alsu b(~ seen .in varicella and herpes zo~ter. 'Those
with geGltal., anaJ, or perianal ulcers should be
scn~encd
for syphilis and herpes; consider
Haemophilus ducreyi if this is !Qcally prevalent.

Laboratory testing for syphilis includes dark fic.Jd
examination (at least once daily for 3 days) and
syphilis serology (vida infra). Management of herpes
labialis include~ oral or topical antiviral agents,
sunscreen, zinc oxide crea1n, and topical anesthetic.
agents.
Table 11 li15\s recommended anti-viral treatmcm
for HBV genital infection. Topical amiviral therapy

Trichomonas vagin.alis
There are 5 m illion STD cases in the US due tv
trichomoniasis; hal f arc asymptomatic in females and
it is found in 5% ofmales att.eDding <:! STD dini!;; (1519). Prevalence in 18 to 26 y~~ar olds is -;2,8 % in
females and 1.7% in Jnt!les. Three trichomon.as
species are identified in humans: T bucca.lis in the
mouth, T hominis in the gastrointestinal tract, and T
vaginalis in the genital tract. Trichomonas vagi.na!is i.s
a unicellular, t1age11ated protozoan which commonly
causes a vaginitis and cervicitis with secondary
vulvitis and urethritis. Trichomonas vaginalis is
spread sexually including through c lose genital
contact.. It h?..s been noted to survive for a fev,r hours in
wet towels. The incubation period is 4 ...30 d ~ys , after
which genital tnct infection occurs involving the
vagina, cervix, bladder; urethra, Skene's (periurethral)
and Bartholiu;s glands. The vagina is erythematous
and contains a profus~~. greenish (or gray or yellowgreen), frothy ("htibbly"), malodurou.s discharge. Jt is
intensely pruritic with a pH of 5.0 .. 5.5 or h!gh~)r, A
mucopumlent or turbid vaginal discharge may be
noted in 10 to l5% but this can also be seen with
herpes simplex infection, chfarnydia infectivn and
gonon'hea.
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[""ij·:·ii:~-t -episode (tontiu~~~-~;~~;--1(i'd_;~.-s if 1esions not fully resolved)

·-··.· ····~-------··················-···--·

..----··-.--····-····--··-!

i

a. Acyciovi.r, 400 mg, oraUy, three times a d<>y fin 7.. 1() days, or
b. Acyclovir, 200 mg, orally, five times a day for 7-10 days, or
i
c. Valacyclovi.r, 1 gram, orally, two times a day for 7-10 days, or
i
d. Famc[dovi.c, 250 mg, orally, ;:htee times a day for 7-10 days
2. Recurrent epbod~s {shortens dundism uf lesions)
a. Acydovir:
-SOU rng, crally, two times a day, for 5 days
-400 mg, orally, three times a day for 5 days
-800 mg, orally, tl1ree times a day for 2 days

!

i

~

i

OR
b. Valacyclovir
-1 gram, orally, nnce a day l{;r 5 days
-5DO mg, orally, twice a day for 3 day$
OR
c. F?mciclovlr
-125 mg, orally, two times a day for 5 days or
- ) 000 mg, orally, twice over one day or
-50D mg orally; then 250 mg orally twice a day for 2 days
3. Suppressive l\-'lanllgemeut {teduces freqmmcy of :rccu:rrcnces)

a. Acyclovir, 400 mg, orally, two ti..'11es a day, or
h. Famciclovir, 250 mg, oral!y, two times a day, or
c. Va,lacyclnvi.r, 1 gram OR 500 mg, orally, once a day(valacydovir at 500 mg may be less effective for

those~:: ~..?_?pi.sod_e:_.;/.::..y_e_a....:r):_____~-·-··----·---------·----·--------·------·--·--·-·-·-·-·-·-·----·------------------~------------------·--------------i'Strawbeny marks" (vaginocervical ecchymosis-2%
of infections) and swollen vaginal papUlae are classic
for trichomoniasis. There may be vaginal bleeding
,~·ith genital trauma from C.:)itus or even touching the
genital area with a cotion swab. Dysuria is frequent
and severe cas(~S may present with 1ow abdom(;ml
pain as well as excoriation of the vulva cr im;er
thighs. Adniesccnts may be more prone to severe
symptomatology
than
adults.
Postpartum
trichomoniasis has been noted with fever, leukorrhea
and endometritis. A prolonged calTier state is po&slb.!e
and may be associated \Vit:.1 menses ~ induced, acute
cx~ccerbations, as well as chronic pelvic congestion,
dysnwnorrhea and menorYhagia.
The diflcn:ntial diagno~is includes vu1\ravaginitis
due toN. gonorrhoeae, Candida albkans, or bacterial
vaginos!s. The pres(..>t1Ce of the leukorrhea or cervical
infection is not enough for diagnosis. For example,
what appeurs as an "inflamed" cervix may tx~ a benign
cervical erosion in \:vhich the endocervical columnar
epithelium spreati5 out oftbe cervical canill, forming a
border around the external os.

The saline drop/wet mount (sensitivity of 6070%), Papanicolaou smear and/nr cuiturc (most
sens;tive) can aid with the diagnosis. A saline
prepamtion reveals numerous pcar~shc.ped motile
microbes which are unicclluls.r flagell;~ted organisms
twice the size nf a white blood ceiL These microbes
niay not be seen in chronic ca..1Tiers if urine is the
sarnple study or if the patient used a chemical douche
prior to the exam. The 1u.brka.r:t used on the spe(:ulmn
can ah>o hinder this test result. These organisms can
also be noted in urine samples or on Papanicol<Jou
smears. However, the Pap smear can result in false
negarlve .. as well as false positive results. Cultures
are possible in some laboratories; these are helpflil in
suspicious cases wlth mu!tlple negative saline
preparations. 1'-DA-de<>red tests include OSOM
Trichomonas
Rapid
Test
(color
immunochromamgraphk fdipstkk! technology) ar:uJ
Affirm VP III; the latter is a nucleic acid p-::ohe test
t~'}r T. vaginalis, C. albkans, at1d G. vagina1is.
Treatment is with nitroimidazoles such as
metronidazole and tinic!a10Ie. Metronidazole car,. be
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given as. a single two gram dose or tinidazole is given
at 2. grams orally in one dose; ~m altemati ve regimen
for mettonid~tzo1e is a 7 -day oral course (500 mg
twke a <lay). Tho<>c who drink alcohol need to avoid
this substance during trcatm.cnt and for up to 24 hours
after taking metronidazole and 72 hours after tak~ng
tinidazole. Treatment '.Vith metronidazole gel should

be. avvide_d~
FoHmv-up ts not necessary if the dinical
symptoms rapidly resolve while the uncommon
resistant infection (not rcinfecticm) can b(~ tre:1ted with
thG 7 day course (500 mg BID) of metrrmidazok; if
the infection is still mH resolved, 2 grams (single
dose) of metronidazole is given once a day for 3-5
days. {2010 STD Guidelines, CDC). Vaginal infcctiort
is associated \vith adverse pregnancy outcomes and
pn~gnant patients with T. vaginalis vaginitis can be
treated with the single lwo gram dose regimen of
rnetrorddazole. Those v:ith an immediate-type anergy
to metronidazole can be treated with desensitization.
Resistnnce to nitroimidazoies remains limited.
Metronidazole does have numerous sidr;: effects
including monilial vaginitis, confusion, ataxia,
nat~sea, anorexia, headache, dizziness, transient
neutropenia, metallic taste; dermatitis, diy mucosal
sttrfaces,
urine discoloration. and periphetai
neu rapath y.
Flushing and nausea with emesis occurs when
metronidazole is combined \Vith alcohol due to a
disulfiram effect The single 2-gram dose may redu~~c
many of the side effects for the disulfiram effect.
Tinidazo1e side effects arc similar to metronidazdc
but also tnclude post-marketing reports of severe
dermatological
reactions
including
erythema
muhiforme and Stevens-Johnson syr:.dwme. As noted,
avoid alcohol f()r 72 lwurs after taking tinidamle.

Bacterial vaginas is (B V)

t
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In this scxualiy-assndated (or enhanced) infection,
there is an iacreased growth of anaerobic bacteria in
Lhe
vagina,
including gardncrcHa vaginalls,
mobi.luncus species, bacteroides species, p:revotdla
sp, ureaplasma, and others; Mycophtsrnas hcminis is
also noted while lactobaciHi are reduced . BV induces
ll. vag!nitis characterized by a non-itchy, gray-white,
frothy, tnillodol'ous vaginaJ discharge with a pH
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usuAly less than 4.5; specific cervical or biadclcr
infection is not found. HV can be noted in as many a<s
50% of sexual ass<iUlt victims evaluated >Vithin 72
hours of the assault (23). Transient gardnereila
vagina!is bacteremia has alsn been seen, usua11y
associated v<iith delivery or abortion. ln ~exual1y
activ<~ individuals the presence cf BV also increases
the risks tor gonococcal, trichomonaL and chiamydi<~l
genital infcdion in addition to HrV and H.SV-2. The
frequency of coital behavior and numbers i.)l scxua1
partners may be factors for BV acquisition in some
females.
Clinically, the vaginal discharge, vaginal pH,
Whiff test, and wet mount fbi clue cell~ are used f~!r
the diagnosis of BV Gram stains of vaginal fluid,
typically only obtained in research studies, reveal
decreased Lactobacilli and increased anaerobic
bacteria. A saline preparation or Gram stain of the
leukorrhea. identifies due cells -·-· cp!thclia.i cells
covered ("studded'') with many Gram-negative bacilli;
a positive sample is when 20% O( more of the
epithelial cells are covered wit:.'l bacteria.
'the sensitivity of the wet mount test is 70-90%
(versus 75-80% for the low pH) and spcciGchy is 95·toO% (versus 60-70% for the low pH test). A lessproven test is producing an a.rnine-Jike odor when a
small amount of this discharge is mixed with l 0%
potassium hydroxide (KOH) solution (vlhiff test).
There 1s also a DNA probe to detect high
c:onccntmtions of G vaginal is; the Atlirm VP HI test,
as noted earlier, can det(~Ct G vaginalis.
Table 12 lists the 2 010 CDC recommended
treatment options fvr symptomatic BV. fi)]low-up bf
non-pregnan_t patients with BV w1w resolve with
recommended treatment ls usua.Hy not necessary.
Thete ate n:o recommendations to treat the male
partner of the female '"'ith BV and it remains debated
whether or not to treat asymptomatic BV in pregnant
women without a previous history of preterm
delivery, since it does not prevent pretcrm labor and
delivery.

Human papiilomavirus (HPV)
Human PapWornavi rus (HPV) is a double-stranded
DNA virus t..'lat ac:coU:.'1ts for 20 tnUlion or more STDs
in the United States (6-9).

.:. ~;
:

:' :~
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12. M;magetneutof Dacterial Vaginosis (CDC STO

Guidelim:~g,

:20Hl)

J~rer~~:red"-("N-or;~:p;:;g:n;~nt, ntlT!-lac1atir.g)------------------------------------·-~----~-----------------------------------------------

Metronidazole (500 mg Bm orally for 7 days) OR
Cli.udamycin cream (2%) (one full applicator [5 grams] intrava.ginaUy before bedtime for 7 ch.ys) OR
Metronidazole gel (0.75%) --one full applicator (5 grams) irltravaginaHy, once a day for 5 days.
j Al.t.enrative (Non-pregnant, non-lactating)
l
Tinidazole (2 grams oraHy om:c daily for 2 days OB,
Tinida.zn!c (1 gram. orally once dally for 5 days) .Q.R
Clindamycin -· 300 rng 'wally twkc a day for seven days O.R
Chndamycin ovules (100 mg intravaginally once at bedti.i1le for 3 days)
Preferred (Pregnant)
Mettonidazole (500 rng oraHy, twice a day, for 7 day~) OR
Metronidazole (250 :mg orally, three times a day, fbr 7 days) OR
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ , _ _ _ _ _ _......J
L..__ _
C_J_in_d~~~~0-- 300 mg orally BfD for .seven_9_ays

l

HPV subtypes arc idcntifit:d with an immunobbt
typing systeni; more than l 00 typ<;s are now
recognized, incbding these ofkn associated with
clinicHl symptomatology with approximately 40 that
iritcd the genitals and ~lt !east 14 that are oncogenic.
Types 6 and 11 lead to genital condylomas and type
16 is the most common cause of anogenit.a.l cancer.
Other oncogenic types inciude 18, 31,33,35,39, 45,
51, 52, 58, 59, 68, 73, and 82. There is an incubation
pedod of a few weeks to several montl-H;; it infe.cts
basal epithelial ceHs. Hi~ sexually transmitted and is
often associated with other infections (C albicans)
and STDs (q.s trichommliasis and gonococcal
cervicitis),
HPV is noted (n 3-8% of unsc1ected young
female patl.cnt-;; 25--50% of patients seen in a sexually
tran<:mittcd disease clinic -..vcrc noted to have HPV
using colposcopy. As many as 70% of these particular
patient's sex partners displayed warts or had them
before. Biologic risk factors f()r acquiring HPV
include the presence of cervical cctopy, micro trauma.
and immature immune response capacity. Most HPV
infections are acquired early in the sexual lite of the
patient and adolescents may be more vuherahle to
this infection thrm ad1ilts, from a biological vie\vpoint
Viral protein transcription leads to various HPV
manifestations: warts. dysplasia, and cancer. The
riPV \V<Lrt lesion may involve any part of the genitals
(including the vagina, urethra, bladder, or anal canal)
and the infection can be very extensive. They seem to
worsen in individuals with vaginal di5charge, poor
hygiene, heavy perspiration, aod pregnancy. Lesions
resistant to treatment are reported in some individuals

with insulin-dependent diabetes mdlitus and with
immunosuppressive disorders,
Most HPV
infections
in humans
arc
<isymptomatic and are only dctecLcd by colposcopy or
pap (Papanicolaou) smear testing. Thus, the
prevention of liPV in.f{~Ctions w[th the HPV vaccines
is recommended for females and males from ages 9 to
26 year::; of ag{~ "in contrast" to treatbg the ;va.ti.S or
cancer that develop after the infection. The bivalent
vaccine (Ccrvarix) offers protection against HPV
types 16 and 18 whik th~ qu.adriva.lent vaccine
(Garda.sii) offers protection against HPV type~> 6, I I,
16, and 18. The quadrivalcnt va.ccine provides
protection against the two most common HPV strains
that cause genital warts. The vaccine is a three dGse
seties and co.n1mon side eftects include fever,
injection site reactions, arthralg.ias, and f<itiguc.
Syncope sometimes associated with tonic--donk
movements or other seizure-like activity has been
rcpvrted and observation of the patient for fifteen
minutes after administration is recommended.
The Bethesda system LSlt (low-grade squamous
intraepithelial lesions (LSlL) corresponds to the
WHO ClN ((·.ervicaJ intracpithdial neoplasia) l
classitkatkJD versus HSl.L (High-grade squamous
intra~pithe)i;).l h:f>im:) re!1ect~ CTN II a:nd 111 HPV is
necessary f(y the development, maintenance, and
progression of ClN; HPV is linked to cervical and
vulvar neoplasia as ·well :~s anal cancer, penile car.cer,
and oropharyngeal cancer. Though the timing of
starting Pap sn1ears is controversial, rhe Arnerkan
College
of Obstetricians
and
Gynecologists
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recoramends initial Pap smear scrccnh1g at age 21

regardless of t.he sexual history.
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The di ffere·nt!al diagnosis l}f HPV \varts. indudes
mol!usn.lm coniagiosum, condyloma lata (syphilis),
s.kin tags (peri--anal), urethral prolapse, and. pc::trly
penile papules. T he presence of squarnous papillomas
in moist mucocutaneous areas of the external gcnitaha
and perianal regions is usuaHy sufficient for its
diagnos is. Biopsy is confirmatory <md mandatory if
lesions are rc~.lstaJ'1t to podophyllin therapy. Voiding
cystomethrcgraphy will demonstrate if intra1..iretlmd
spread has occurred. Co lposcopy is used by some
clinicians but there ar~ probJ~ms with access and cost
Cytology (Pap smear) is the most practical diagnosl.ic
toot but has low sensitivity and specificity. Molecular
diagnostic modalities include in situ hybrk!ization,
dot-blot (commercially available ViraPa,p/Vira Type),
Southern. bl.ot and PCR. The PCR (polymerase chain
reaction) is the most sensitive test for HPV. H)•hrid
Capture is FDA~approved to evaluate i 4 high risk or
cancer..assoclated HPV types.
Table 13 llsts the therapy options for warts.
Therapy of concomitant STDs and using 10-25%
tincture of podophylli n (podophyllum resin. in tincture
of benzoin) on the ksions may be helpful, especially
if the ateas are less than 2 em in diameter. White
pctro.laturn jelly may be then added and this mixture
of podophyllin and white pcttolatmn jelly is
thoroughly washed off ln 2-4 hours. There ate other
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techniques for using podophyllin but tht~se all stress
that normal tissue must be protected from. the caustic
podophyllin that induces pain. \Veekly applications
may be necessary and seems to be most effective with
moist, fleshy, sessile genital warts.
The rt)le of more f.requ~nt appli~a,tian h urid\:r
study and the goal of treatment is to rernove the
symptomatic wart. Regrcssioh is .noted in 79% within
2 years and there is no evidence that treatment of
overt warts afi:ects the development of cervical
cancer. Persistent infections are associated with
:;moking, other STDs, multiple partners and
immunosuppression states.
Podophyllin is not used for cervical warts or for
pregnant patients. If there is not regressio n after G:>LU'
weekly trials, other metJ1ods are used. U"nfottl!nately,
there is no treatment proven to er;tdicate this virus and
no specific regimen to ahvays remove Ute warts and
ptevent recurrences. In ?.dditioh, no ()ne treatt!lellt

su.ites

all

patients

~nd

th~rapy

should

be

individualized.
The use of topical chemotherapeutic agents (as
80-90'% tric hloroacetic acid [OK for pregnancy and
m~1cosa] or 5--fluoro.uracil) has been used as
alternatives to topical podophyllin t reatment
Podofilox (U:5%) i;; availabl~ t(~r h~m1e use; others
inciude Irniq11irnod 5% cream and Sinecatechins 15%
ointment None of the at-home treatments have beea
adequately assessed in pregnancy.

Table 13. Trea.tme11t Options for Exlern:d Gcnitll.l W arts (2010 CDC STD Gtli.ddi..ucs}

---·-·-·---- - - - - - - - - - - - - - - - - - - - - --------·-·-·-·-·--------·-·----:
A. TOPICAL APPLICATION
!
Prttient··applied.:
Podof11ox 0..5% solution.or gel

Imiqui.mod 5% cream
Sinecatechins 15% ou1tment

Cryotherapy w!th liquid nit.:rogen or cryoprobe

Podophyllin resin lD%-25% (in compound tin{;nm: of benzoin)
Trichloracetic acid {TCA) or Bi.chloroacetic acid (.BCA) S0%-90%

i
i

ll
l

;
;
1

B.OTIIER
Surgi~:a!

removal ofwar!s

lntr<\let;ional interferon injectior
Laser surgery
Topical cidofovi.r

;
;

;
;
j
1

i

'----~--------------·····""""""" .......... ... ... . ...... ............."'""'"'·······--··..························--·--·--·--··-· .............................. ... ......... _. •..• _.--<
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Methods which have been recornmcnded. as
alternativeS" to podophyllin therapy include curettage,

e!ectrocautenz:aticn, loop ekctrcsmgic~1 exclSlon
procedur e (l.EEP), alfa i11terferon, surgical excision;
and cryotherapy (with liquid nitrogen or solid carbon
dioxide). immunotherapy with a11 4utogenous v accine
(prepared from excised warts) has been attempted but
i.s without proven success. Laser treatment has also
been used with succe!>s. Careful tollow-up of these
patients is important, due to the Hn:k of this virus to
cervicn1 cancer and other cancers.

Table 14. No:rma! Flora of the Vagina after Puberty
·-·-··-----..--·-··]

Dodt."f.leih's lactobaci!!i.

'j

Bnte.::ob;:1ctcriac,~ae

!

Bacteroides .fi"agilis

i

Neisseria sicca
Streptococci (i.ncluding gtoup B)

!
i

ii
!I

Stapbylcicocci
Diphtheroids

Ccmdida .albicans
Other yeasts
Other anaerobic bacteria
Other
microbes
............................................................................

i
i

_._______,I

Vulvovaginitis

Physiologic leukvrrhea

Pt;berty exerts a profound estrogen effect on the
female genital ttact that produces a thicket, longer
vagina. with a:n adult effect on tb9 vaginal cell count:
approximately
60%
superficial
cells,
3l ~;;;
in termediate and 9% parabasaL
The pH: is in the acidic range (5.0 to 5.5) due to
lactic acid production partially f.rom the presence of
Lactobacilli (Table 14). One rcsul.t of th is thickened,
acidic vaginal milieu is increased protection against
infection. Vdvovaginitis tends to be due to specitic
causes (Table 15), many of which are covered earlier
in this chapter. The prese.nce of cett ain identified
pathogens (i.e., neisseria gommhoeac, trichomonas
vagina lis, cundida alblcans, gardnerella vagim~Iis)
do cs not always mean a.symptomatic ir.fection exists;
sometimes a 'triggering mechanism (<)fien not known}

Physiologic leukorrhea re fers to a normal increase in
vaginal discharge (leukorrhea) due to a pubertystimulated increase h estrogen prodtfction; it can also
be noted in the flr~t few days or weeks after birth in
the female newborn due to maternal estrogen .. in early
pnberty the vaginal 4ischatg¢ is from. muct:S sectetion
of the cervical coiU.ml1<U' epithelium, vaginal \VaU
fluid trar.sudatior;, and multiple gla11d stimulatio11
(i.e., Bartholin' s, st:baceous, and sweat). Classically it
initiates several weeks or months prior to menarche
aod is variabl.~ in amount until regular menstt'1.1ation is
established. The leukon·hea rs typically dear, sticky,
and non-irritating and may increase during pregnancy
Pr even during

se>wal ar<.rv.!iai.

must occur before •wert symptomatology occurs.
Table 15. Cause~
•••••••• •• • •~~ -. , ....,. ,

nfVuivmraginiH~

_ _.....,,~H••••••••••••••• •••• • •••••• ..., o ..., _ _ _ _ _ ...,,, ., ,,,,, ,, , , ,,, ,,,,,,,,., ,....,,...., ~---~•-••• •••••••••••• •••••-••••• ••••u ooo.oooo oooooooo o•••••••••••••••• ._,. •-•

1. Leukorrhea nnd/or vaginitis
a. Physiologic leukorrhea
b. Candida alhicans vaginitiS.
c. Bacteria[ vaginos!s

._........4:..!.'~t.C:.?!!~~'J!!.~~q~ vagin~!!.·~-\~.lli!.Jj_~~--·--·· ·------- .........................

_____

..,_..............-------..-----·-··-····2. Cerv(citis dtte to
a. Chlamydia trachomatis
b. Neisseria gonon·hoeae
c. flerves sim lex ~~~in1s
........_,,_____.. _.,, .. _,,_,,,...._....._ _ _ _________ , ....... _ _ _ __ _ _ __ _ _ __ _, ___,.......................... ..

!----,--c-::"---...._~--.:.

3. Miscella,'1em:s
a. Allergic vulvcvagillitis
b , Foreign body vaginitis.
c. Vulvar ulcerations (herpes, syphilis, ch:mcroic, lymphogranuloma venereum gn:nt:!oma. ingui~~ale , amebiasis,
Behcet's syndrome, others)
d. Vulvitis (scabil"s,. molluscum contagiosum , pecHc~iiosis, warts [HPV], tinea, psoriasis, furwJ]cuJosi~ , pruritu:;

..........Y~.}:!Lvac, othSI_~L.._...................._ ..___.._..............................._______
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A saline preparation of the vaginal fluid rev{~al.s
1wm1al vaginal cytology without leukocytes ot
pathogenic bacteria. Cultures of the 'iaginal t1uid arc
not necessary but, if obtaip.cd, arc negat ive. The
young adolescent female may be concerned that it is
due to genital injury or a sexually transmitted disease.
Nylon undergarments absorb the t1 u1d poorly in
conti'ast to the excellent absorptive powers of cotton
illldergatr!lenis.
Good
perineal
hygiene
is
recommended and norrnai baths and medication
shouid be avoided; inadvertent nse of rnedication car)
lead to such sequelae as dermatitis medicamentosa.

Ccmdid(t alhica.ns
Vu lvovaginal candidlasis (VVC) is a common cause
cf vulvovaginitis no! ci<'.ssi:fi:cd a<; a sexully
tn;nsmitted ciisease and dne to Candida albicans in 8090%, Torulopsis glabrata in 10-15% and C.
parapsUosis in 1-2%. Table 16 lists various
precipitating factors in the development of recurrent
ar chronic VVC. VVC typically p:-escnL'> with v;:tginovu!var erythema, intense pruritis, and a whitish,
cottage checse..Jike v:1gina! dis chargt:: 'v\'ith a pH of3.8
to 5.0 (typically <4.5). Itchiness with erythema and
decrca~ed !eu..'wrrhea tnay occur if the infection is
pre~ipitated hy antibiot,ics; more leukorrhea occurs if
VVC deveiops dttri ng pregnancy. Increase in th::.

discharge may occur before un.d after menstruation
but may decrease during m enstruation.
Other sym ptoms tl1at may occur include urinary
frequency, dysuria, and dyspareunia. There may also
be fissuring, lichenification, a11d secondary bacterial
infection over the perineal areas or legs (inctuding the
ihighs). Skene's glands and endocervical glands :may
also be infected. The prcsem:e of thkkcned, bronzed,
or dul.l red skin over the labia or groin suggests
chronic infection. .Oerma1op.hytids (Mor.j1ids) can
develop as very pruritic but sterile lesion:> at the sides
ofthe fingers and hanck Laboratory testing reveals a.
vagitmi secretion with a pH under 5.0 while a 10%
KOH preparation shows hyphae (mycelia), pseudohyphae (non-detached buds), yeast (1Jvai cells), and
possibly white blood ceHs; the exruu js negative f(:)r
clue cells ~nd trichornonads. Culture can ;:;!so be
accomplished. The o nly FDA-approved oral
medication ls flt;conaz,o.le ·Jmt is given as 150 mg

tablet (Table J 7). A number of azole agents
available as topical agents, as noted in Table 17
are. oil-based and thus, may ·weaken. latex
.
and diaphragm~. Topical. azolcs aj'e consid(:n~d rn6re
eftective tbau nystatin and arc recommended for use
during pregnancy; short courses ( l -3 days) are as
eft(lctive as longer courses. C. albicans. cru:t be tound
i n as rnany as 20% of females without VVC
symptoms and <H'lti-fungal t reatment is usually net
i:ndkated ill this situation. Treatment of sexual
p~tttners of fcrna.les with symptomatic VVC is not
recommended unless she has re.c urrent or chronic
disease. A lltinority of male sex partners of fbnules
with v-'/C may develop balan.itls th&t usi~aHy resolves
with topical anti fungal agents; other potential causes
of balanitis include herpes simplex virus and primary
syph ilis.
Femal~s with recurrent VVC due to C albicans
may be managed wi1h a s ho1i cvilrs~ of fluconizoie
(100 to 200 rng every 3 days fm 3 doses) or oue to
two we~ks of topkai agents ; longer '"rnaintcnanec''
antifungal treatment may be considered (20 lO CDC
STD
management guidelines).
Most
have
nncomplicated VVC. Complicated VVC is not wcl1underst0od and involves those females with recurrent
VVC (4 or more episodes per year..···found in <5%),
severe \lVC, non-a1bicaus candidiasis, or those with
uncontrolled diabetes mellitus or immunosuppression
states. Females with nou-aJbicans VVC can be treated
with nor).-fluconazole azcle drugs (txal or top ical) for
7 to l4 days, Numerous drug i nteractions exist with
oral azoic agents due to cytochrome .P 450 enzy me
metabollsm and i.nhibition. A patient's medication
regimen should be revie\Ned fot drug intcmctim.'ls
before initiating an oral azole medication. If further
infection occurs, use boric acid {600 mg) in a sciatiJl
capsule intravagi.nally, once a day, for J4 days(!).

Miscellaneous STDs
Many other STDs are noted in youth . Group A
streptococci can cause a vaginitis in prepube1tal
female::; after t ransmission by sexual contact or
autoinoculation from Lhe pharynx; managcmet:t is
with 10 days of penicillin.
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Tab(f.16. Predpitllting Fa<-tors for Chronic ur Re~~-:nent VVC'
'

~.

2.
a.
b.

c.
d.

,.,
,)

e.

.

Aging
Severe iron deficiency anemia

Imtutme disorders
Chrvnic Candida exposure

a.

b.
c.

Infected se.:( prutner
Contami;1ated soap~
Intestinal reservoir

In<:re<lse in heat qr moisture

4.

a.
'b.
5.

Rednction of host defense mec]l(!,"lisrn
Chronic illness
Steroids

Obesity

Tight nylon undergarments
Lmver the p.H

a. Pregnancy
b. Oral comrayeptives
L - -e-. -Diabetes Mellitus
..,_, ........................................- .......................

- -------- -- - ----............................

Tahle 17. Mznage.m~n t of Vulv ovaginal Omdidiasis (VVC)

,..T..

oj~}~;g·~~i~".fi~couazoi"~*

( I somg oraJtab)

i~-

a singJc

ci~.~~-----........................_...................................

l

2. ClotrL>nazole:
-cream {1%) (5 grams) iniravagina!Jy for 7-14 day;; or
-cream (2%) (5 gmms) intravaginally for 3 days
3. Mjconazoie nitrate:
.. vaginal cream (2%) once daily (5 grams) for seven days
-vaginal cream (4%) once daily (5 grams) fi)t three days
~200 mg vaginal suppository, one suppositoryfortbrec days
-100 mg vaginal suppo:ritory, one suppositmy fiJr seven days
,
i,',,

I
[

i

I
i

~ l ,200 mg vagir:al.~uppository..---us.e once
4. 2% butaconazole nitrate (Femstat) cream -- 5 grams given [ntravaginaHy for three d.ays.
s_Otht.m: include tioconazole and terco nazole* and (\S topical agents.

~

i
i
i

--~·
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·.;
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i

~pres<:ription only __..............................................-....- ...............--~-----

!

··:·:

·rablc 18 cutiines treatment for pediculosis pubis (due
to Pthirus pubis) and scabie.s (due to Sarcoptes
s~abiei). Increasing resistance w ith perrnetbrin and

pyrantef pamoa·te (Mwprescription: l t mg/kg with
'maximum of l gram orally; r~peat in 2 weeks) OR
with prescription medications: mebcndazo.k (i 00 mg

pyrethrins may require use of malathione if treatment

tablet once and ma.y need to repeat in 2 weeks) or
albendazole VlOO mg tablet and repeat irt 2 weeks;
unlabeled indication). All famity m embers in dose
contact with the patient should also be trcatt~d .
Lymphog ranul,oma venereum (LGV) is an STD due to

failu.re occurs for pcciiudm.is pubis.
Due to t.t1e neurologka.! toxicities associated with

llndane, permethrin and i vermectin are considered.
first line trt:atments for sc;>bics. LindanQ and
ivcnnectin should not be used du;-ing pregnancy.
Pi:tlwOrrns (Enterobius vermiculatis) may (,;.ause- rcctai
and vaginal irritation as well as pruritus. The won:r:s
may be found in the perianal area at night or
identified with the cellophane tape test. Treat \-vith

infection with Chlamydia tTachcmat1s

(~erotypes

L1 ,

L2, and LJ ) with an incubat ion period of3 to 30 days;
it callses inguinal 1ymphadenfJpathy (buboes) that is
painful as. wel! as genital ulcers and severe ukerative
proctitls (proctocoliti~) . The pl'imary lesion may be a

.::.:

I'
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transmitted diseases

smal1 red erosion (oilen missed) with fever, malaise,
myalgias, and arthralg!::::.s. Unilateral lymph nodes
above and below the inguinal ligainent are called the
"groove" sign. fTntreate4 LGV can lead to bo\vel
obstruction, bowel perfora.tion, rectal strictures, an.d
even death. Molecular testing is availabk to establish
a diagnosis of LGV vvhill~ t.re;~trnen.t irwolves
doxycycline (1 00 mg orally, twice dally, t~1!' XI day:~);
an alternative plan is ~rythromycin base (500 m.g
mally QrD for 21 days). Erythromycin should be used
Juring pregnancy a.nd in lactating femaJes.
Chancroid. (due to haemaphilus ducreyi) has an
incubation period of 3 to 14 days and presents with a
small, painthl, erythematous papule that classically
erodes into a r~.gged ulcer with undetermined edges;
there is usuall~' painild, often uniiRteral, inguinal
lymphadenopathy
tlut may
be
Sllpporative,
Laboratory data may include culture (often difficult to
obtain) and PCR testing. Management Is with
ceftdaxone (250 mg TM), dprotloxac in (500 mg HID
f~':lr 3 day.s) or azithrom ycin (1 gra;.-n orally); an
ahernativc plan is erythromycin base (500 mg TID for
7 days). Fluoroquinoionc.s should be avoided during
pregnancy and in lactating females.
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Granulo_ma inguirtale {donovanosis) is du.e to
hf'ection with K1cbsleHa granulomatls (formerly
called Calymmatobacterium gnmu1omatis) that has
incubation period of 2 to 10 weeks and presents with
an erythem;:;.tous nodule or papu1e that is usuaHy nonpairtf'lll but then utcerates to form friable, beefy-red
granulation tissue; tisslle b iopsy can note Donovuan
bodies. Inguinal lymphadenopathy is not nsua11y
noted b'1t perilympha tic g.ran.nlomas ("pseudobubos")
may mimic enlarged lymph nodes. lt is treated with
doxycycline (J 00 mg oraiiy, twice daily, for at least 3
\-Veeks) OR I 60 mg of trimethop1im with 800 mg of
sttlfm:nethnxazok ---nne tablet orally, twice daily, for
3 weeks). Alternative trec.tments include ciprof1oxacin
(750 mg orally, twice a day, fat 3 weeks),
erythromycin base (500 mg, orally, four times a day
for 3 weeks), or 3.zithrmnycin (l gram orally, per
week, for 3 weeks). ln pregnancy, erythromycin is
pteferted
and
inclusivn of an intravenous
aminog,lycoside shm:dd be considered. Treatment
should continue until all lesions have completely
bea1ed and relapses can occur despite appropriate
treatment.

:r.

T.

:~: ..

!

A. Pediculosis pubis
Permethri.n (t% cream rinse--·--app'ty to affected areas; 1.-vash off in 10 minutes) OR
Pyrethrins (with piperonyl butoxide··--·appiy to affected areas; wash off inlO mim;t:es)
.-~ltemative:

I:

:t

Ivlalathione (0.5% lotion applied for 8 to l2 hours; wash off) OR
Ivermectin (250 meg/kg oraUy; rep"at in 2 weeks)

::::::
::~; :

:t:

:·~ ..
::~..
::~: :
::~: :
:·~: .·.

:}:

1
!!

!

H. Scabies
Pennetltrin* (5% ~rcarn~apply ti·cm neck down; wash off in 8 to 14 hours) OR.
!vennectin* (200 meg/kg oraily; n:pe<J.'- ill 2 weeks)
A lternativc
·---~~Lindane* (1 %): i oz (30 gr;;m) of cream applied in a l.hin layer to ail arqas from the neck down, wash off
thoroughly ai:ler !\ hours; d~l not apply directly after bathing.

I
l. . ~~J)-~~EE.~P..t)_i:~L?.'ll:i........._.....................................................................-----~-··
Syphilis Is an STD of antiquity due to Treponem<:1.
paHidurn with an incubation period of 9 to 90 da ys
(average of3 weeks) (25). This pathogenic spirochete
gains access via mucos~.i abrasions during sex ual
activity "vith the indlJction of a Iocal immune response
and secondary hematogenous spread. P rimary syphilis
presents with the classic chancre that is a well-

...........- ...................... ________.........J

defined, painless, etythemataus ulcer with a firm
(rubbery)
base;
there
JS
usually
inguinal
lymphadenopathy that can be bilatetai or unilateral,
<l.nd typically nontcndcr as \Vell as non-suppurative.
Diagnosis is \Vith darktield microscop~.r to
identify the trcpm1cmcs and serology (non-treponr~mal
tests: R.FI\., VDRL). The sensitivity of R.PR or VDRL
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is r..il!her in secondary syphilis versus primary o r
la1cnt syphilis; also, RPR and VDRJ.. arc associated
with ii1lse ppsitivc results and false negative results
(nrozone react! on). Direct fluorescent antibody testing
(i>F/bTP) of smears can also be used i.f available.
ireponemal tests can be used: fluorescent treponema\
antibody
absorption
(fTA-ABS)
.and
tn icroh~magglutination assay (MHA-TP) that rem ain
positive for a lifetime il1 m ost (despite treatmet:!?Screen those \Vit:h a history of expo~ure to syplul!S
with an RPR or VDRL and if positive, do a
treponema! t:~st(i . e.~ I\1HA-TP or FTA·ABS).
The chancre lasts 2 to 6 weeks and wiLl resolve
even without treatment. Secondary sy philis appears 6
weeks to 6 inonths after disappearance of the chanc:re
and ca.'1 present with a wide V(lriety of constitutional
syrnptoma.tology in Its role as the "Great Imitator":
malaise,
fever,
generaJized lymphadenopathy,
heoatospenomegaly, . rhinitis. sore throat, alopecia
('';,oth--eaten:", patchy), polymorphic rash (with or
without involvement of the palms and soles),
headache, arthralgias, anogcntial condy'l omata lata,
and many others .
The .rash of syphilis may begin as a .red, l~ac_ular
eruption first on the extr~ruities and trunk; l{\Slon:s
may become elevated w ith .a copper-red hue and
· ns
involve the palms as well· as so l es ..{0 1a.que- I'1ke ';csJo
may be seen that mimic psoriasis while the
appearance of rings CaJl. mi.rnic ~"inea c-orporis.
Condyloma iata appear as skin-colored or gray,
macerated papules in the perianal or genital an~a;
there can also be mucous patches that present a.~ oval,
gray erosions on tiw genital areas or in the oral cavi:Y·
Secondary syphilis can la.<;t 2 or more weeks and also
resolves wlthout treatment. Later stages can occur that
&.i'(~ rarely seen in adolescents_
. induding early latent
tw ithln one year of inJec:tion), late latent ((:an pt~rsl.st
for n1any years v.·ithout symptoms). latent syphilis of
unkn(W·itl duration; and tertiary (neurologic, cardiac,
gurnmatous lesions).
.
t'rimarv. se»ondary, a..•Ki early latent stage-s ot
syphiJis ar~ treated w ith Benzathir1c Pe nicillin G {2.4
million u;1ils lM) in one dose; late latent, latent
syphilis of unknown duration, and tertiary syphilis
(not 11eurosyphilis) arc treated with Benzathine
Penicillin G (2.4 million units fM) weekly for th ree
weeks. Neurosyphilis ~>hould be treated wit..i:J
intravenous penicillin G (18-24 minion units per day)

for 10-14 days. A patient with syphilis who is allergic
to peniciilin is desensitized and treated with
penici!lin. Altematlve treatrnent in non-~pr~gnant
individuals is tetracycline {500 rng, orally, four times
a day) or doxycyciine (l 00 mg, oraHy, twi«e a day)
for 14 days. An acute febrile reaction called the
Jarisch·H~rxheiml!r reaction can occur within 24
hours of initiating treatment; this is typically seen in
·
· · · ', · ··-~ ' sypn
· ''l'
. j can bt:
' man<tge
· · --~·d w>•h
pahents
Withe~,~
~ ,s anu
. ••• ,
antipyretics. Se~ the CDC STD Ciuidelines (20 10) fnt
managen1e n.t of syphHls including neurosyphilis,
tertiary syphili.~, lat~nt syphiLis, and congenital
syphilis.

Homosexuality and STI>s
in adolescents
Homosexual hqhavior rnay occur during adolescence
and eventually, ~- to 6% of adults wl!l identif,Y
themselves as gay, le.s!an, or bisexuaL Young
adolescents may only .filld homosexual contact at
nubile places wh<;'!re pmblems with sexually
~ransmlrt~d dL;eases (including HIV infection) often
exist
Lesbian teens may have sex w ith males as part of
their adolescent sexual experimentation and some are
at increased risk of HTV infection as well as other
STUs b~ausc of coitus with infected males;
pregnancy risks also occur in this situation if
unprotected sex occurs.
" About 25% of those with lilV/AIDS in the
lbited States contracted their infection by the age of
21 ye<n·s. For these in tl1eit twenties with HTV. many,
if nnt most of thM1; wetc infected while they were
still teenagers .or in thtlir e•1rly twenties (see lhc next
scc:tion). Even if tlu: adole.sc.cnt engages in same-sex
behavior for economic reasor\s and not because of
being homoc'>exual, risks f()r STDs remain. Advice
r'·'•.rrFdin!!.
testing for sexually transmitted diseases
"'-'f,.
includes explaining possible risk factors, treatment
options, and discussion regarding confidentiality as
well as intOqning the adolescent's parent, if possible.
Advice regarding opti ons for self protection
includes safe sex llwareness and practke, including
sexual abstinence <>.nd use of Jatex condoms, In
addition, the adolescent can he taught techniques to
handle peer pressure r~;:g(l.rding sexual behavior.
~
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The gastrointestinal trad can h~ invofved \Vlth
acquisition of STD agents in rectal (receptive} sexulil
activity. Proctitis (rectal inflammation) is noted with
anoredal pain, retial discharge, and tenesmus due to
N gonorrhoeae, T pallidum, HSV, C trachomatitis
(induding LGV scrovars), and others. In proctocolitis,
there is abdom]nal cramping, diarrhea, and symptoms
of rectal intlanimation due to various agents (Table
19).

In enLent1s due to various opportumst1c agents
(Table 20), there is mainly abdominal cramping and
diarrhea; giardia l:nnblia is the most common cause in
this sin1ation.
Tr~atmcnt depends on the causatiw <J.gent(s). In
proctitis suspected to be due to N. gonorrhoeae
treatment is with ceftriazone (250 mg [M) and
doxycycline (100 mg orally, twice a day for 7 days) to
cover C. trachomatis. Consider herpes and LGV
scmvars a~ causative of rectal ukcrs and treat
acco;·dingly; use 3 weeks of doxycycline (TOO rng
ora1ly, twice a day) for LGV treatment Sec the 20!0
CDC STD Management Gu.iddines (1).

Iluman Immunodeficiency Virus/Acquired
.Immunodeficiency !';)ndrome (l!IV/AJDS)
Ovt~rail, 1 rnHH.on individuals are t~~timated to be
infeded with the human immunodeficiency virus-1
(HJV-1) in the "United States with at least one-third
seen in those 15 to 29 years of age; approximately
half of new infections are found in those under age
25. HiV-2 is prevD.l<)llt in West Africa. Minority
populations suffer dispropc}rtionatdy higher numbers
of H.lV infection. This virus ls transmitted via .:>~xual
activity, needle sharing, and aiso in breast milk.

The main mode of transmission in tna1es lwving
HIV 1s males having s~Cx with males (MSM) often
'v<iith injection drug use, though it can affect any
gender or age group that is exposed. The introduction
of z1drn'udine (formerly caned azidothymldLne
[_abbreviated AZTj) has greatly reduced mother-tochild tranc;mission atthis time.
Primary risk categories in adolescent females and
young \Vomen for HIV infection include heterosexual
bdsavior complicated by injection dmg use. Another
group of HIV-infected adolescents is those who were
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infected prenatally awi a(e now in the adolescent age
group.
Testing inv()!ves t~se of the HIV EIA/Westcrn
Blot and should be done a!;cordi;lg to lo;~al statt:
guidelines for mv testing ( 1).
Generally antibody testing initiates with a.
screening test such a.s an enzyme immunoassay (EIA)
and then reactive screening tests are cnnfirrned with a
test
s:uch as the Western
Biot test or
LmmnnoftuorcSC(\nCC a%ay
A).
A continued positive test )ndicates the individual
is infected with this virus (HTV) ard can infect others.
Seroconversion usual.ly occurs within 3 months aftm'
infection but may take up to 12 mont.1s; a negative
testing scheme does not rule out a recent infection.
Plas.ma EIV RNA testing {plasma viral IGad test or
PVL test) can be obtained in situations when a patient
has symptomatoicgy consistent \Nlth acute HlV
infection but HTV antibody testing is negative or
inconclusive. The RNA viral load test mcasure.s the
amount of free HTV virus (non cell bound) in the
infected person.. Follow-up testing (i.e., WGstern Blot)
can be done in two to four months t0 .:-onfirm HIV
infection if tbc pia~ma mv piasma testing indicates
HIV infection.
Though most newly diagnosed patients are
asymptomatic, some can develop acute rctrov.[ral
syndrome (ARS) 2 to 6 \veeks after HlV infection
before f{fV tcsdng becomes positive. A variety of
symptoms are noted including fever, malaise, skin
rash. and lymphadenopathy.
These youtll may benefit from early usc of anti-HlV medications (antitretroviral drugs) and should be
rcfct(ed to local experts in HlV management The
patient with AIDS has the development of an
oppt!tiurdstic infection (jr AIDS· defining ailment ih
one infected v.'ith HIV or a drop in the patient's CD4
lymphocyte count to 200 ceUs/mm3 or less.
Thos(: with Hl V/AIDS develop a vvid.e, protean
variety of potential symptomatology and disorders
including
generalized
lymphadenopathy,
hepatomegaly, splenomegaly, failure to thrive, oral
thrush, recurrent diarrhea, hepatitis, parotltls,
c:ardiomyopathy, nephropathy. c:enlral nervous system
disease, Iy1:nphoid interstitial pnccunonla {UP),
recurrent invasive bacterial infectJ(Jn:;;, opportunistic
infections, and malignant neoplasms.
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Antiretroviral

management

(ART)

very complex ~ituation with ever-changir.g protocols
recommendations, Detailed discussion of
manage;ncm is beymid the scope ofthis article.

1s

recommended for all those with HIV and A1DS and
referral to local experts in an HIV//\IDS cemel' is
recmimJendcd. to ensure the best treatrnen.t

t~;r

at'"lJ

thi.;

________................-.........................----------.............................................................................................................................

~ --ur.eili-ri-t-:is

i

Neissaia gonorrhoeae
Chlarnyci;(J tradwmatis

f

:
:

'i

,1yf_vcoplasma genitalium
Ureaplasma urea!yticum
Trichomonas vagina/is

i
i
i

i
i
i

i

Herpes Simplex Virus

!

J~dcnov~ru~es

!

i

Pharyngitis
Neisseria gonorrhoeae
Herpes ,'hmplex Virus

!

Treponerru"l pr;lllrlum

!
!
!
~

!

!'
i,,,',,,_

Others
Acquired immunodeficiency syndrome or AIDS (persons wi:th l·UV i.ntection may acqu1re v<>rious other
opportunistic infections not listed)
Genital warts (infection with human papillomavirus [HPVD
Ectoparasites (Pthl:tus pubis; Sarcoptes scabzei)
Hepatitis
Hepatitis A, B, C, D, andior E virus
Cytomcgaloviru5
Epste[n-l:.larr virus
Ulcerative lesions
Syphilis (Treponema pallichrm)
Herpes simplex virus (HSV)
Chancroid (Haemophilvs dv.creyi)
Lymphogra.nuloml.l venereum (Chlamydia trachomatis)

Gram.tloms. inguinale (Klebiella granufomatis)
Enteritis/proctocn litis
Giardia la.rnbli.a
S'alnwnelia enteritidis
Entamoeba histolytica
Cryptosporidium species
Campy!t>bacter species
Shigellr1 species
Chlamydia tnzcho.rnatis
LGV serovars
~
~~~~~~.~-....~
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Table 20. AnHretroviral Mcrlh~~~ti~ns (Par-tial Ust)
r-:;:--·---·--·······················----·-·<-······----····························-·-·-:--·-·-·-·-·-·----- - - -- ---·-·-··--···--·-----·--··-·······---·--·······--··-·-·
A. Nomiudeo~ide Rever~e Tnmsc.ri.ptasc Iuilibitm·s (NNRI1s)

Efavi.renz
Nevirapine

Dctaviridine
Etraviri.n.c
Ri lpivirine

B. Protea§e Inb:ibitQr S (Pis)
Atazanavi.r
Danmavir

Fosamprenav :r
Lopinavir
Saquinavir
Tipnmavir
Ritonavit
Indin.avir
Ne!finavir
C Nucleoside R everse T ra11script8se lnhlbitun• (1\iRTls)
Ahacavir

Emtrlc!tabine
Larnivudine
Tenofovir
Zidbv~:di nc

Didanos.ine
Stavudine
D. futeg:r aise Strand T:nmsfel:' lnhH:ritor (ISTE)
Ra.ltegr<Jvir
E. Cellu.!ar C hemokinc Receptor 5 A~tagomst (CCR.~ A.tltagonist)
Maravlroc
:.__
, .....................................................................

____________

AutiTetrovirai medications are generally d ivided into
t.ive diffcrc.r.t groups (Table 20) and ways to improve
adherence tc this regimen are listed in Table 2L
Detalled
instructions
arc
provided
at
ww\~·. aidsinfo.ni.h.gov and it is vital to provide a
program with \Vell-t;~ined health care prof~~ssiona1s
who adhen; to up-d<.Ued _protowls. T'he 1ncdications
al'e compiex with many side effects and drug
interactions.
Compi.icat!ng r.he overall treatment is the many
potential oppnru.mistic infections that may be seen
that can be dinicuit to treat. ·rhe patient should rnakc
a commitment to a lifetime of treatment that will
result in the best possible life span and quality of Hfc,
especially as t1.eW discoveries are made with rcsenrch
now and in the future.
Classificatio n is based p!·edominantly on the CD4
count and ditJercnt protocols may be used ha.s ed on if

~------

the palit:nt has or has not i·eceived. ART (ART-nai've
versus ART-expcdcncd); anot:\er import.ant factor is
the plasma HlV RNA load. Genotype tesling is
recommended to op1imizc regimen selection due to

the potentia! Dx drug resistance,
Ea1·1y ART treatment helps to protect the pathmt'!:i
sex partner from becoming intected with HIV; correct
condom usc with aU coitus js alsG important in this
preventive scheme. Combinatior;, of ARTs is more
effective than monothcrapy and protocols g.cncra..lly
use 3 antiret:-ovira! drug.!.-~ frorn. twc) different ;;J<J..s:>e~ ,
sueh a~ including 2 N'RTls along with a protease
inhibitor or 'Nl\JRTI (Table 20) .
fr: dividnalizing therapy is essential a11d attempts
are made to simplifY the treatment protowl to
maximize compliance with the treatment protocols
(Table 2 1).

.

.;

~:

:·:

.
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D onald E Greydan.us, J-ane Seyler. Hatim A Omar, et ai.
Tabil! 21. Strateg~es to Impr.ove Adh~-~·ence to Antiretrovb·al T hera·py Strat~:gies:

.F rom .h ttp://www.aidsinfu.nih .gov/Content.Filcs/Adu!taudAdokscentGL.PJ)K Asse..o;sed May 12,2011. Tal>le i:z
r:-l=-Ts_e_a_m_u-=ltidi·~-~if;l"i~a~y-t~in1appr-oac:h·-----------------.,-.-N-u:-,r-s-es-,-s-o-cia-lw"Z;;:k;[~, pharrnaci~ts, a~~T~:-edication

-l

----------------------------------------------1

Provide an accessible, tn1sting. health care team \ Immagers

·Establish
Es_:~~)~~~h:~:~~~~I~i~~:~~~i~~~~ir~~:i1~jE~::P.~~~nt
readiness to start ART

--------------------------------------------------------------------------I

j
ldcnti ry potential ba•riers to adJ:crcnce prl()I' to--T·~·-p-;~y-(:"i~~;;~;;·;;~-ris~~;~-~-------···············starting ART
J • Active substance r,buse or at high risk of rdapse
! • Low literacv level
'
! • Busy daily sd~Qduk and/or travel away from home
• La-ck of disclosure ofH1V d[il.gnosis
• Sb;nicism abotltART
• Lack of prescrlption drug coverage
--·········-·;·R_~-f~-~~~-fo~·m;nta"Ci~ca.ith aJ-'1--:di O-"r:...s_u--:1-}S_ta_·1-lc--e-abc:--_l-l.-Se-. _tr_e_a_tm-en_:_t.......;
.t1·cvide resources for the patient
• Res.ourves to obtain _prescription dmg coverage
• Pillboxes
-ln v.ol ve the-patie1£jj_1-antiretrov lral (ARV')""-········· ··;·j::~~r·~·aa;·;_~pJ;;;·:·r~~:~e·w--p~;t~~nt ial side effects, dosiog
regimen se1ectiPl1
frequency, pill b:.u-dGn, storage. req1Jiremen:ts, food
i requirements, and consequences of non--adl1erence
----........,,...-,,....-~----- - ·· · ·· ··· <···-········· ···············································-------·--·· ------:-----:---:-----l
Assess a:dhcrcncc at cvct·y clinic visit
Use a simple checklist the patien~ l)att <;omplcte in the
waiting room
i " ffave ott~er 1nen1be-rs of the hea1th cart~· t~an1 also. assess
',·

1,,

•

i adherence
j

1•

.
• Failure to fjll tbc pre:scription(s)-··--···········-·································------···l

t······················----- - ---·-·································---·
l identify t...i-te type of non ..~dhcrencc,
1

1

j
j

> ••••••••••••••••••••

Ask the patient open--ended questions (e.g., In the fast 3 days,

l please tell me how ymi took your medicines.)

,.,_.___._,.,..,. w- - " ••

i Identify reasons for nonadherenc~ ; assess and
j simp !i fy regimen, if poss iblc
:

• Faiiurc t.o take the right dost~(s) at t."lerigi1t time(s)

t:~::;:~:;~~~;::~~~~;i:.~:~::~~~:;::;.:,
:
;
I·
Difficulty swallowing large pilis
! • I;orgetfulness
j • Failure to unden;tand dosing instructions
iI • lna.deq;1ate
understandL'1g' of (.h~Jg n::si.stam;.e and. its
.
i n:latior:sh.ip to adherence
!
Pill fatigue

li

I

I

!•

: • Other potential barriers {see list_~!~~-':~2

I

1. . . . . . .. . . . .. . . . . . . . . . . .- - - - -- - --- ·--·-······ · · · · ·.· · · · · · · · · · · · · ····· · · · · ·· - - .

......................·-----~----~---··

Conclusion

Ackno'wled.g:mcnts

High rates of unprot.ccted sexueJ behavicr in
adolescents result in n1rHions of sexually lnHJsmittcd
diseases (STDs) h the world. This paper reviewed
fc1.ctors iJJ.ducing .high STD rates, specific STDs, and
their management ba~ed on 2010 US Centers for
Disease and Prevention (CDC) ST.D guidelines.
CHn!:,:ians should screen all their sexually active
adolescent patients for STDs and provide preventive
educa.ti.on as wdi as treatment measures.

This paper is an adapted version of a chapter in tb~
book "Adolescent medicine: Phaq_nacotberapeutics in
general, mental and ~exual h,,~alth., edited by Donald E
Grcydanus, Dilip R Patel, C~mthia Feucht, Hatirtl A
Omar, Jmw Mer-rick and publ ished with pc:rmissi0n
by Walrct d.c Gruytcr, Berlin and New York.
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